These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35308835)

  • 1. Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.
    Beshir SA; Aadithsoorya AM; Parveen A; Goh SSL; Hussain N; Menon VB
    Int J Alzheimers Dis; 2022; 2022():9343514. PubMed ID: 35308835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
    Yuksel JM; Noviasky J; Britton S
    Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
    [No Abstract]   [Full Text] [Related]  

  • 3. Aducanumab: evidence from clinical trial data and controversies.
    Tampi RR; Forester BP; Agronin M
    Drugs Context; 2021; 10():. PubMed ID: 34650610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
    Mukhopadhyay S; Banerjee D
    J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.
    Haddad HW; Malone GW; Comardelle NJ; Degueure AE; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(1):31925. PubMed ID: 35928986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
    Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
    Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.
    Brockmann R; Nixon J; Love BL; Yunusa I
    Lancet Reg Health Am; 2023 Apr; 20():100467. PubMed ID: 36908502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis.
    Terao I; Honyashiki M; Inoue T
    Ageing Res Rev; 2022 Nov; 81():101709. PubMed ID: 35961514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
    Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
    Neurol Ther; 2021 Dec; 10(2):919-940. PubMed ID: 34426940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
    Varadharajan A; Davis AD; Ghosh A; Jagtap T; Xavier A; Menon AJ; Roy D; Gandhi S; Gregor T
    J Neurosci Rural Pract; 2023; 14(4):566-573. PubMed ID: 38059250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aducanumab in Alzheimer's disease: A critical update.
    Ashique S; Sirohi E; Kumar S; Rihan M; Mishra N; Bhatt S; Gautam RK; Singh SK; Gupta G; Chellappan DK; Dua K
    Curr Med Chem; 2023 Jul; ():. PubMed ID: 37497712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
    DiStefano MJ; Alexander GC; Polsky D; Anderson GF
    J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aducanumab: Appropriate Use Recommendations.
    Cummings J; Aisen P; Apostolova LG; Atri A; Salloway S; Weiner M
    J Prev Alzheimers Dis; 2021; 8(4):398-410. PubMed ID: 34585212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future.
    Esang M; Gupta M
    Cureus; 2021 Aug; 13(8):e17591. PubMed ID: 34646644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aducanumab: First Approval.
    Dhillon S
    Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle.
    Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S
    Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aducanumab for the treatment of Alzheimer's disease.
    Tagliapietra M
    Drugs Today (Barc); 2022 Oct; 58(10):465-477. PubMed ID: 36305541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab.
    Chin E; Jaqua E; Safaeipour M; Ladue T
    Cureus; 2022 Nov; 14(11):e31065. PubMed ID: 36475205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.